Vesicle-associated protein that interacts with G-alpha (GIV) as a predictive marker in stage II colorectal cancer

摘要

Method for analyzing a stage II colorectal cancer (CRM) competent for mismatch repair (pMMR) sample obtained from a subject, comprising: contacting a sample comprising stage II CRC pMMR with a specific binding agent a vesicle-associated protein protein that interacts with full-length G-alpha (GIV-fl), in which the protein-specific binding agent GIV-fl comprises an antibody against GIV-fl, or contacting isolated RNA from a sample with a nucleic acid probe specific for vesicle-associated protein mRNA that interacts with full-length G-alpha (GIV-fl); score the expression of mRNA or GIV-fl protein in the sample to determine a GIV-fl state of the sample; determining the lymphovascular invasion (LVI) status of the CRC in the subject with a specific binding agent that allows a determination of LVI in which the specific binding agent that allows a determination of LVI comprises a specific antibody for CD34 or lymphatic endothelium; and analyzing the sample based on the GIV-fl state and LVI state, in which the method further comprises determining the sample's mismatch repair status (MMR) with the binding agent specific for mating repair protein. erroneous, wherein the erroneous mating repair protein-specific binding agent comprises one or more antibodies specific for mutL 1 (MLH1) homolog; increased postmeiotic segregation 2 (PMS2); MutS 2 protein homolog Msh2 (MSH2) and / or MutS 6 protein homolog (MSH6); and in which the method is a method of predicting the probable progression-free survival (PFS) of the subject, in which more LVI and high GIV-fl levels are associated with a higher probability of recurrence.